No. | Age | Diagnosis (WHO, FAB) | IPSS | Karyotype | Pretreatment | Total no. cycles | Response | Cytogenetic response | Cycles to response | Response duration/months | Dose reductions | Status | Survival |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
D05a | 69 | CMML II, CMML | Int-II | +8 | Hydroxyurea | 23 | CR | CR | 9 | 20 | Aza 75% | Dead | 26 |
D03a | 73 | RAEB II, RAEB | Int-II | Normal | None | 18 | CRdys | na | 2 | 20 | Aza 50% | Dead | 23 |
D04a | 72 | sAML/MDS RAEB I | Int II | Complex (incl. −7) | None | 6 | CRdys | PR | 1 | 9 | none | Dead | 11 |
D06a | 64 | CMML II, CMML | High | del(7q) | None | 43 | CRdys | CR | 2 | 44 | Aza 50% | Alive, ongoing | 44 |
D17a | 67 | sAML/MDS, RAEB-T | High | del(20q) | None | 19 | CRdys | CR | 9 | 16 | Aza 50%, VPA reduction | Dead | 30 |
F03a | 77 | AML de-novo | X | +21 | Intensive chemotherapy | 10 | CRi | CR | 8 | 13 | VPA interruption | Dead | 13 |
D14a | 77 | sAML/MDS, RAEB-T | High | Normal | None | 24 | CRdys | na | 5 | 29 | VPA discontinuation | Dead | 36 |
D01a | 69 | sAML/MDS RAEB | High | Complex (incl −7) | None | 4 | PR | nd | 1 | 19 | VPA discontinuation | Lost to Follow up | 19 |
D15a | 74 | RAEB I, RAEB | Int-II | −7, dup 1(q) | None | 5 | PR | PR | 2 | 4 | VPA discontinuation | dead | 6 |
F02b | 87 | AML de-novo | X | Normal | LBH589 | 3 | SD, marrow CR | na | na | 2 | VPA interruption | dead | 2 |
F05b | 59 | sAML/MDS, RAEB-T | High | Complex (incl −7) | Intensive chemotherapy | 3 | SD, marrow CR | none | na | 3 | VPA interruption | allo-PBSCT - > CR, dead | 13 |
D11b | 74 | t-AML | X | +6,+8 | Epo | 5 | SD, marrow CR | none | na | 8 | Aza 75% | dead | 9 |
D13b | 72 | sAML/MDS | X | Normal | None | 6 | SD, marrow PR (blast count: 34 → 8%) | na | na | 8 | none | dead | 9 |